Hereditary Cancer Testing Market By Cancer Type (Breast Cancer, Ovarian Cancer, Colon cancer, Stomach Cancer, Head & Neck Cancer, Prostate Cancer, Pancreatic Cancer, Melanoma, and Others); By Test Type (Single Gene Testing and Multi-Gene Panel Testing); By End Users (Hospitals, Clinics, Diagnostic Centers, and Others); By Region (North America (U.S., Canada, Mexico, & Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden & Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), & Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore & Rest of Southeast Asia), & Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, & Rest of Middle East & Africa) Latin America (Brazil, Argentina, & Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Hereditary cancer cases are increasing due to mutation in the genes. The early detection of hereditary cancer enable patients to seek early treatment. Rising demand for early detection and accurate diagnosis is a major factor propelling the hereditary cancer testing market growth. Efficiency and cost-effectiveness over traditional testing methods is also driving the growth of the global market. Other factors contributing to the market growth include surge in the demand for the DNA testing kits, increasing usage of genetic data, increasing technological advances, government support towards hereditary cancer testing, and increasing growth of medical infrastructure.
Ethical and clinical issues of DNA tests are restraining in the growth of global hereditary cancer testing market. Due to difficulties regarding legal issues in accessing the complete genomic data for early detection and prevention, the growth of the hereditary cancer testing market is likely to slow down. However, various companies are spending extensively on research and development activities to explore and introduce new methods to overcome the clinical issues, along with the legal options to address ethical issues, within the purview of legal framework in the market in future.
Hereditary cancers are those type of cancers, which due to gene mutation, are inherited by children at birth from their parents. Even if the parents are not suffering from such type of cancers at the time of conceiving but are prone to it, then the child would be born with genes that would make him prone to cancer. Testing for hereditary cancers can help doctors to detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers in a person. Hereditary cancer testing allows doctors to conduct an in-depth cancer risk assessment for each patient. The critical goal of hereditary cancer testing is to detect cancer early and to give doctors, the opportunity to maximize health outcomes for his/her patients by trying all types of treatment. Along with these, preventive measures and proactive treatment are possible through hereditary cancer testing for patients of a high-risk group. Early diagnosis increase the chances of better overall prognosis through a choice of surgical treatment options and non-surgical treatment options.
Technological advancements for exome sequencing are expected to boost the global hereditary cancer testing market growth as DNA sequencing, along with its advances are paving way in the research field by introducing remarkable advancements in genomics. Compared to whole genome sequencing, the whole exome sequencing is quicker and more cost-efficient. In terms of revenue, hereditary cancer testing market was valued at US$ 6051.37 Mn in 2020 growing at a CAGR of 6.2% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Hereditary Cancer Testing Market Revenue & Forecast, (US$ Million), 2015 – 2029
Cancer Type Outlook:
As per the cancer type, the global hereditary cancer testing market is segmented into breast cancer, ovarian cancer, colon cancer, stomach cancer, head & neck cancer, prostate cancer, pancreatic cancer, and melanoma, amongst others.
The breast cancer segment accounted for the largest market share in the global hereditary cancer testing market in 2020. Approximately 7% of breast cancer cases are caused by mutations in the BRCA1 or BRCA2 genes. People carrying a mutation in either of these genes suffer from a condition called hereditary breast and ovarian cancer (HBOC) syndrome. They have up to 87% risk of developing breast cancer by age of 70. If the people carrying such mutation have already been diagnosed with cancer, they are significantly at a higher risk of developing a second cancer in the future. Due to advancement in medical science, the early detection of breast cancer along with the adequate treatment is becoming feasible, which is accelerating the growth of the global hereditary cancer testing market. One of the most common cancers in the world, breast cancer affects almost 12.5% of women during their lifetime and 5% to 10% of these patients suffer from this cancer due to hereditary reasons. New advances in genomic technologies have made parallel testing of multiple genes feasible. With customized next generation sequencing panels, the simultaneous analysis of breast cancer predisposition genes is possible. Such genes range from high penetrant genes to intermediate penetrant genes. Thus, this development in genomic technology is estimated to contribute towards the segment’s growth in the global market over the future years.
Test Type Outlook:
In the context of test type, the global hereditary cancer testing market has been primarily segmented into single gene panel testing and multi-gene panel testing. The single gene panel testing segment accounted for the largest market share in 2020.
The multi-gene panel (MGP) testing segment is expected to witness highest growth rate in the global hereditary cancer testing market during the forecast period. In the context of inherited cancer susceptibility, the hereditary cancer multi-gene panel testing is seen as a new paradigm in clinical genetic testing. Encompassing simultaneous analysis of a larger number of genes, this model targets specific cancer sites that include breast, colorectal, endometrial, gastric, melanoma, ovarian, pancreatic, and prostate. MGP testing has also reduced the cost of genetic testing due to next-generation sequencing (NGS) technology.
End Users Outlook:
On the basis of end users, the global hereditary cancer testing market has been segmented into hospitals, clinics, diagnostic centers, and others. The diagnostic centers segment accounted for the largest market share in hereditary cancer testing market in 2020. Increasing establishment of diagnosis centers providing testing facility to patients along with ease of accessibility owing to their distributed geographical presence has favored the segment’s growth in the global market. However, hospitals and clinics are anticipated to witness substantial growth over the period of next eight years.
Region Outlook:
North America accounted for a significant share in the global hereditary cancer testing market in 2020. However, during the forecast period, the Asia Pacific region is expected to become the fastest growing regional market due to increase in affordability, rise in awareness toward early screening of hereditary cancer, and surge in healthcare expenditure. Other factors contributing to the market growth in this region include increasing development of medical infrastructure in Asian countries such as Japan, Singapore, & South Korea and governments of Asian countries like China & India encouraging more research for technology for hereditary cancer testing.
Competitive Landscape Outlook:
The report provides both, qualitative as well as quantitative research of global hereditary cancer testing market. It also provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as affiliations, collaborations, mergers & acquisitions (M&A), and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global hereditary cancer testing market are Ambry Genetics, ASPIRA WOMEN'S HEALTH, CENTOGENE N.V., Color Health Inc., Fulgent Genetics, Illumina Inc., Invitae Corporation, LifeLabs Genetics, Myogenes Limited, Myriad Genetics Inc., NIPD Genetics, and Otogenetics, amongst other market participants
Global Hereditary Cancer Testing Market:
- By Cancer Type
- Breast Cancer
- Ovarian Cancer
- Colon cancer
- Stomach Cancer
- Head & Neck Cancer
- Prostate Cancer
- Pancreatic Cancer
- Melanoma
- Others
- By Test Type
- Single Gene Testing
- Multi-Gene Panel Testing
- By End Users
- Hospitals
- Clinics
- Diagnostic
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Hereditary Cancer Testing Market
6. Market Synopsis:
Hereditary Cancer Testing Market
7. Hereditary Cancer Testing Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Hereditary Cancer Testing Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Hereditary Cancer Testing Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Hereditary Cancer Testing Market
8. Global Hereditary Cancer Testing Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Hereditary Cancer Testing Market Revenue (US$ Mn)
8.2. Global
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By Cancer Type
8.2.1. Breast
Cancer
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Ovarian
Cancer
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Colon
cancer
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.2.4. Stomach
Cancer
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2020
8.2.4.5.5.2. Market
Forecast, 2021 - 2029
8.2.5. Head and
Neck Cancer
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2020
8.2.5.5.1.2. Market
Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2020
8.2.5.5.2.2. Market
Forecast, 2021 - 2029
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2020
8.2.5.5.3.2. Market
Forecast, 2021 - 2029
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2020
8.2.5.5.4.2. Market
Forecast, 2021 - 2029
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2020
8.2.5.5.5.2. Market
Forecast, 2021 - 2029
8.2.6. Prostate
Cancer
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2020
8.2.6.3. Market Forecast, 2021 - 2029
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market
Estimation, 2015 - 2020
8.2.6.5.1.2. Market
Forecast, 2021 - 2029
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 - 2020
8.2.6.5.2.2. Market
Forecast, 2021 - 2029
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market
Estimation, 2015 - 2020
8.2.6.5.3.2. Market
Forecast, 2021 - 2029
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 - 2020
8.2.6.5.4.2. Market
Forecast, 2021 - 2029
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market
Estimation, 2015 - 2020
8.2.6.5.5.2. Market
Forecast, 2021 - 2029
8.2.7. Pancreatic
Cancer
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 - 2020
8.2.7.3. Market Forecast, 2021 - 2029
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market
Estimation, 2015 - 2020
8.2.7.5.1.2. Market
Forecast, 2021 - 2029
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 - 2020
8.2.7.5.2.2. Market
Forecast, 2021 - 2029
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market
Estimation, 2015 - 2020
8.2.7.5.3.2. Market
Forecast, 2021 - 2029
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 - 2020
8.2.7.5.4.2. Market
Forecast, 2021 - 2029
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market
Estimation, 2015 - 2020
8.2.7.5.5.2. Market
Forecast, 2021 - 2029
8.2.8. Melanoma
8.2.8.1. Definition
8.2.8.2. Market Estimation and Penetration, 2015 - 2020
8.2.8.3. Market Forecast, 2021 - 2029
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.2.8.5. Regional Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market
Estimation, 2015 - 2020
8.2.8.5.1.2. Market
Forecast, 2021 - 2029
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2015 - 2020
8.2.8.5.2.2. Market
Forecast, 2021 - 2029
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market
Estimation, 2015 - 2020
8.2.8.5.3.2. Market
Forecast, 2021 - 2029
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market
Estimation, 2015 - 2020
8.2.8.5.4.2. Market
Forecast, 2021 - 2029
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market
Estimation, 2015 - 2020
8.2.8.5.5.2. Market
Forecast, 2021 - 2029
8.2.9. Others
8.2.9.1. Definition
8.2.9.2. Market Estimation and Penetration, 2015 - 2020
8.2.9.3. Market Forecast, 2021 - 2029
8.2.9.4. Compound Annual Growth Rate (CAGR)
8.2.9.5. Regional Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market
Estimation, 2015 - 2020
8.2.9.5.1.2. Market
Forecast, 2021 - 2029
8.2.9.5.2. Europe
8.2.9.5.2.1. Market
Estimation, 2015 - 2020
8.2.9.5.2.2. Market
Forecast, 2021 - 2029
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market
Estimation, 2015 - 2020
8.2.9.5.3.2. Market
Forecast, 2021 - 2029
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market
Estimation, 2015 - 2020
8.2.9.5.4.2. Market
Forecast, 2021 - 2029
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market
Estimation, 2015 - 2020
8.2.9.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Cancer Type
9. Global Hereditary Cancer Testing Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By Test Type
9.2.1. Single
Gene Testing
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Multi-Gene
Panel Testing
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By Test
Type
10. Global Hereditary Cancer Testing Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By End Users
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Clinics
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Diagnostic
Centers
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By End
Users
11. North America Hereditary Cancer Testing Market Analysis and
Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America
Hereditary Cancer Testing Market Revenue (US$ Mn)
11.2. North
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Cancer Type
11.2.1. Breast
Cancer
11.2.2. Ovarian
Cancer
11.2.3. Colon
cancer
11.2.4. Stomach
Cancer
11.2.5. Head
and Neck Cancer
11.2.6. Prostate
Cancer
11.2.7. Pancreatic
Cancer
11.2.8. Melanoma
11.2.9. Others
11.3. North
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Test Type
11.3.1. Single
Gene Testing
11.3.2. Multi-Gene
Panel Testing
11.4. North
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By End
Users
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Diagnostic
Centers
11.4.4. Others
11.5. North
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
11.5.1.1.1. Breast Cancer
11.5.1.1.2. Ovarian Cancer
11.5.1.1.3. Colon cancer
11.5.1.1.4. Stomach Cancer
11.5.1.1.5. Head and Neck Cancer
11.5.1.1.6. Prostate Cancer
11.5.1.1.7. Pancreatic Cancer
11.5.1.1.8. Melanoma
11.5.1.1.9. Others
11.5.1.2. U.S Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
11.5.1.2.1. Single Gene Testing
11.5.1.2.2. Multi-Gene Panel Testing
11.5.1.3. U.S Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
11.5.1.3.1. Hospitals
11.5.1.3.2. Clinics
11.5.1.3.3. Diagnostic Centers
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
11.5.2.1.1. Breast Cancer
11.5.2.1.2. Ovarian Cancer
11.5.2.1.3. Colon cancer
11.5.2.1.4. Stomach Cancer
11.5.2.1.5. Head and Neck Cancer
11.5.2.1.6. Prostate Cancer
11.5.2.1.7. Pancreatic Cancer
11.5.2.1.8. Melanoma
11.5.2.1.9. Others
11.5.2.2. Canada Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
11.5.2.2.1. Single Gene Testing
11.5.2.2.2. Multi-Gene Panel Testing
11.5.2.3. Canada Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
11.5.2.3.1. Hospitals
11.5.2.3.2. Clinics
11.5.2.3.3. Diagnostic Centers
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
11.5.3.1.1. Breast Cancer
11.5.3.1.2. Ovarian Cancer
11.5.3.1.3. Colon cancer
11.5.3.1.4. Stomach Cancer
11.5.3.1.5. Head and Neck Cancer
11.5.3.1.6. Prostate Cancer
11.5.3.1.7. Pancreatic Cancer
11.5.3.1.8. Melanoma
11.5.3.1.9. Others
11.5.3.2. Mexico Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
11.5.3.2.1. Single Gene Testing
11.5.3.2.2. Multi-Gene Panel Testing
11.5.3.3. Mexico Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
11.5.3.3.1. Hospitals
11.5.3.3.2. Clinics
11.5.3.3.3. Diagnostic Centers
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
11.5.4.1.1. Breast Cancer
11.5.4.1.2. Ovarian Cancer
11.5.4.1.3. Colon cancer
11.5.4.1.4. Stomach Cancer
11.5.4.1.5. Head and Neck Cancer
11.5.4.1.6. Prostate Cancer
11.5.4.1.7. Pancreatic Cancer
11.5.4.1.8. Melanoma
11.5.4.1.9. Others
11.5.4.2. Rest of North America Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By Test Type
11.5.4.2.1. Single Gene Testing
11.5.4.2.2. Multi-Gene Panel Testing
11.5.4.3. Rest of North America Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By End Users
11.5.4.3.1. Hospitals
11.5.4.3.2. Clinics
11.5.4.3.3. Diagnostic Centers
11.5.4.3.4. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Cancer Type
11.6.3. By Test
Type
11.6.4. By End
Users
12. Europe Hereditary Cancer Testing Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe
Hereditary Cancer Testing Market Revenue (US$ Mn)
12.2. Europe
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By Cancer Type
12.2.1. Breast
Cancer
12.2.2. Ovarian
Cancer
12.2.3. Colon
cancer
12.2.4. Stomach
Cancer
12.2.5. Head
and Neck Cancer
12.2.6. Prostate
Cancer
12.2.7. Pancreatic
Cancer
12.2.8. Melanoma
12.2.9. Others
12.3. Europe
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By Test Type
12.3.1. Single
Gene Testing
12.3.2. Multi-Gene
Panel Testing
12.4. Europe
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By End Users
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Diagnostic
Centers
12.4.4. Others
12.5. Europe
Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.1.1.1. Breast Cancer
12.5.1.1.2. Ovarian Cancer
12.5.1.1.3. Colon cancer
12.5.1.1.4. Stomach Cancer
12.5.1.1.5. Head and Neck Cancer
12.5.1.1.6. Prostate Cancer
12.5.1.1.7. Pancreatic Cancer
12.5.1.1.8. Melanoma
12.5.1.1.9. Others
12.5.1.2. France Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
12.5.1.2.1. Single Gene Testing
12.5.1.2.2. Multi-Gene Panel Testing
12.5.1.3. France Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.1.3.1. Hospitals
12.5.1.3.2. Clinics
12.5.1.3.3. Diagnostic Centers
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The UK Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.2.1.1. Breast Cancer
12.5.2.1.2. Ovarian Cancer
12.5.2.1.3. Colon cancer
12.5.2.1.4. Stomach Cancer
12.5.2.1.5. Head and Neck Cancer
12.5.2.1.6. Prostate Cancer
12.5.2.1.7. Pancreatic Cancer
12.5.2.1.8. Melanoma
12.5.2.1.9. Others
12.5.2.2. The UK Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
12.5.2.2.1. Single Gene Testing
12.5.2.2.2. Multi-Gene Panel Testing
12.5.2.3. The UK Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.2.3.1. Hospitals
12.5.2.3.2. Clinics
12.5.2.3.3. Diagnostic Centers
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.3.1.1. Breast Cancer
12.5.3.1.2. Ovarian Cancer
12.5.3.1.3. Colon cancer
12.5.3.1.4. Stomach Cancer
12.5.3.1.5. Head and Neck Cancer
12.5.3.1.6. Prostate Cancer
12.5.3.1.7. Pancreatic Cancer
12.5.3.1.8. Melanoma
12.5.3.1.9. Others
12.5.3.2. Spain Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
12.5.3.2.1. Single Gene Testing
12.5.3.2.2. Multi-Gene Panel Testing
12.5.3.3. Spain Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.3.3.1. Hospitals
12.5.3.3.2. Clinics
12.5.3.3.3. Diagnostic Centers
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.4.1.1. Breast Cancer
12.5.4.1.2. Ovarian Cancer
12.5.4.1.3. Colon cancer
12.5.4.1.4. Stomach Cancer
12.5.4.1.5. Head and Neck Cancer
12.5.4.1.6. Prostate Cancer
12.5.4.1.7. Pancreatic Cancer
12.5.4.1.8. Melanoma
12.5.4.1.9. Others
12.5.4.2. Germany Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
12.5.4.2.1. Single Gene Testing
12.5.4.2.2. Multi-Gene Panel Testing
12.5.4.3. Germany Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.4.3.1. Hospitals
12.5.4.3.2. Clinics
12.5.4.3.3. Diagnostic Centers
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.5.1.1. Breast Cancer
12.5.5.1.2. Ovarian Cancer
12.5.5.1.3. Colon cancer
12.5.5.1.4. Stomach Cancer
12.5.5.1.5. Head and Neck Cancer
12.5.5.1.6. Prostate Cancer
12.5.5.1.7. Pancreatic Cancer
12.5.5.1.8. Melanoma
12.5.5.1.9. Others
12.5.5.2. Italy Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
12.5.5.2.1. Single Gene Testing
12.5.5.2.2. Multi-Gene Panel Testing
12.5.5.3. Italy Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.5.3.1. Hospitals
12.5.5.3.2. Clinics
12.5.5.3.3. Diagnostic Centers
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Cancer Type
12.5.6.1.1. Breast Cancer
12.5.6.1.2. Ovarian Cancer
12.5.6.1.3. Colon cancer
12.5.6.1.4. Stomach Cancer
12.5.6.1.5. Head and Neck Cancer
12.5.6.1.6. Prostate Cancer
12.5.6.1.7. Pancreatic Cancer
12.5.6.1.8. Melanoma
12.5.6.1.9. Others
12.5.6.2. Nordic Countries Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Test Type
12.5.6.2.1. Single Gene Testing
12.5.6.2.2. Multi-Gene Panel Testing
12.5.6.3. Nordic Countries Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By End Users
12.5.6.3.1. Hospitals
12.5.6.3.2. Clinics
12.5.6.3.3. Diagnostic Centers
12.5.6.3.4. Others
12.5.6.4. Nordic Countries Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Cancer Type
12.5.7.1.1. Breast Cancer
12.5.7.1.2. Ovarian Cancer
12.5.7.1.3. Colon cancer
12.5.7.1.4. Stomach Cancer
12.5.7.1.5. Head and Neck Cancer
12.5.7.1.6. Prostate Cancer
12.5.7.1.7. Pancreatic Cancer
12.5.7.1.8. Melanoma
12.5.7.1.9. Others
12.5.7.2. Benelux Union Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Test Type
12.5.7.2.1. Single Gene Testing
12.5.7.2.2. Multi-Gene Panel Testing
12.5.7.3. Benelux Union Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By End Users
12.5.7.3.1. Hospitals
12.5.7.3.2. Clinics
12.5.7.3.3. Diagnostic Centers
12.5.7.3.4. Others
12.5.7.4. Benelux Union Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Cancer Type
12.5.8.1.1. Breast Cancer
12.5.8.1.2. Ovarian Cancer
12.5.8.1.3. Colon cancer
12.5.8.1.4. Stomach Cancer
12.5.8.1.5. Head and Neck Cancer
12.5.8.1.6. Prostate Cancer
12.5.8.1.7. Pancreatic Cancer
12.5.8.1.8. Melanoma
12.5.8.1.9. Others
12.5.8.2. Rest of Europe Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Test Type
12.5.8.2.1. Single Gene Testing
12.5.8.2.2. Multi-Gene Panel Testing
12.5.8.3. Rest of Europe Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By End Users
12.5.8.3.1. Hospitals
12.5.8.3.2. Clinics
12.5.8.3.3. Diagnostic Centers
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Cancer Type
12.6.3. By Test
Type
12.6.4. By End
Users
13. Asia Pacific Hereditary Cancer Testing Market Analysis and
Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia
Pacific Hereditary Cancer Testing Market Revenue (US$ Mn)
13.2. Asia
Pacific Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Cancer Type
13.2.1. Breast
Cancer
13.2.2. Ovarian
Cancer
13.2.3. Colon
cancer
13.2.4. Stomach
Cancer
13.2.5. Head
and Neck Cancer
13.2.6. Prostate
Cancer
13.2.7. Pancreatic
Cancer
13.2.8. Melanoma
13.2.9. Others
13.3. Asia
Pacific Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Test Type
13.3.1. Single
Gene Testing
13.3.2. Multi-Gene
Panel Testing
13.4. Asia
Pacific Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By End
Users
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Diagnostic
Centers
13.4.4. Others
13.5. Asia
Pacific Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.5.1.1.1. Breast Cancer
13.5.1.1.2. Ovarian Cancer
13.5.1.1.3. Colon cancer
13.5.1.1.4. Stomach Cancer
13.5.1.1.5. Head and Neck Cancer
13.5.1.1.6. Prostate Cancer
13.5.1.1.7. Pancreatic Cancer
13.5.1.1.8. Melanoma
13.5.1.1.9. Others
13.5.1.2. China Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
13.5.1.2.1. Single Gene Testing
13.5.1.2.2. Multi-Gene Panel Testing
13.5.1.3. China Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.1.3.1. Hospitals
13.5.1.3.2. Clinics
13.5.1.3.3. Diagnostic Centers
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.5.2.1.1. Breast Cancer
13.5.2.1.2. Ovarian Cancer
13.5.2.1.3. Colon cancer
13.5.2.1.4. Stomach Cancer
13.5.2.1.5. Head and Neck Cancer
13.5.2.1.6. Prostate Cancer
13.5.2.1.7. Pancreatic Cancer
13.5.2.1.8. Melanoma
13.5.2.1.9. Others
13.5.2.2. Japan Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
13.5.2.2.1. Single Gene Testing
13.5.2.2.2. Multi-Gene Panel Testing
13.5.2.3. Japan Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.2.3.1. Hospitals
13.5.2.3.2. Clinics
13.5.2.3.3. Diagnostic Centers
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.5.3.1.1. Breast Cancer
13.5.3.1.2. Ovarian Cancer
13.5.3.1.3. Colon cancer
13.5.3.1.4. Stomach Cancer
13.5.3.1.5. Head and Neck Cancer
13.5.3.1.6. Prostate Cancer
13.5.3.1.7. Pancreatic Cancer
13.5.3.1.8. Melanoma
13.5.3.1.9. Others
13.5.3.2. India Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
13.5.3.2.1. Single Gene Testing
13.5.3.2.2. Multi-Gene Panel Testing
13.5.3.3. India Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.3.3.1. Hospitals
13.5.3.3.2. Clinics
13.5.3.3.3. Diagnostic Centers
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New Zealand Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
13.5.4.1.1. Breast Cancer
13.5.4.1.2. Ovarian Cancer
13.5.4.1.3. Colon cancer
13.5.4.1.4. Stomach Cancer
13.5.4.1.5. Head and Neck Cancer
13.5.4.1.6. Prostate Cancer
13.5.4.1.7. Pancreatic Cancer
13.5.4.1.8. Melanoma
13.5.4.1.9. Others
13.5.4.2. New Zealand Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Test Type
13.5.4.2.1. Single Gene Testing
13.5.4.2.2. Multi-Gene Panel Testing
13.5.4.3. New Zealand Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By End Users
13.5.4.3.1. Hospitals
13.5.4.3.2. Clinics
13.5.4.3.3. Diagnostic Centers
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
13.5.5.1.1. Breast Cancer
13.5.5.1.2. Ovarian Cancer
13.5.5.1.3. Colon cancer
13.5.5.1.4. Stomach Cancer
13.5.5.1.5. Head and Neck Cancer
13.5.5.1.6. Prostate Cancer
13.5.5.1.7. Pancreatic Cancer
13.5.5.1.8. Melanoma
13.5.5.1.9. Others
13.5.5.2. Australia Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Test Type
13.5.5.2.1. Single Gene Testing
13.5.5.2.2. Multi-Gene Panel Testing
13.5.5.3. Australia Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By End Users
13.5.5.3.1. Hospitals
13.5.5.3.2. Clinics
13.5.5.3.3. Diagnostic Centers
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South Korea Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
13.5.6.1.1. Breast Cancer
13.5.6.1.2. Ovarian Cancer
13.5.6.1.3. Colon cancer
13.5.6.1.4. Stomach Cancer
13.5.6.1.5. Head and Neck Cancer
13.5.6.1.6. Prostate Cancer
13.5.6.1.7. Pancreatic Cancer
13.5.6.1.8. Melanoma
13.5.6.1.9. Others
13.5.6.2. South Korea Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Test Type
13.5.6.2.1. Single Gene Testing
13.5.6.2.2. Multi-Gene Panel Testing
13.5.6.3. South Korea Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By End Users
13.5.6.3.1. Hospitals
13.5.6.3.2. Clinics
13.5.6.3.3. Diagnostic Centers
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Cancer Type
13.5.7.1.1. Breast Cancer
13.5.7.1.2. Ovarian Cancer
13.5.7.1.3. Colon cancer
13.5.7.1.4. Stomach Cancer
13.5.7.1.5. Head and Neck Cancer
13.5.7.1.6. Prostate Cancer
13.5.7.1.7. Pancreatic Cancer
13.5.7.1.8. Melanoma
13.5.7.1.9. Others
13.5.7.2. Southeast Asia Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Test Type
13.5.7.2.1. Single Gene Testing
13.5.7.2.2. Multi-Gene Panel Testing
13.5.7.3. Southeast Asia Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By End Users
13.5.7.3.1. Hospitals
13.5.7.3.2. Clinics
13.5.7.3.3. Diagnostic Centers
13.5.7.3.4. Others
13.5.7.4. Southeast Asia Hereditary Cancer Testing Market Revenue (US$
Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
13.5.8.1.1. Breast Cancer
13.5.8.1.2. Ovarian Cancer
13.5.8.1.3. Colon cancer
13.5.8.1.4. Stomach Cancer
13.5.8.1.5. Head and Neck Cancer
13.5.8.1.6. Prostate Cancer
13.5.8.1.7. Pancreatic Cancer
13.5.8.1.8. Melanoma
13.5.8.1.9. Others
13.5.8.2. Rest of Asia Pacific Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By Test Type
13.5.8.2.1. Single Gene Testing
13.5.8.2.2. Multi-Gene Panel Testing
13.5.8.3. Rest of Asia Pacific Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By End Users
13.5.8.3.1. Hospitals
13.5.8.3.2. Clinics
13.5.8.3.3. Diagnostic Centers
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By Country
13.6.2. By
Cancer Type
13.6.3. By Test
Type
13.6.4. By End
Users
14. Middle East and Africa Hereditary Cancer Testing Market
Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle
East and Africa Hereditary Cancer Testing Market Revenue (US$ Mn)
14.2. Middle
East and Africa Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.2.1. Breast
Cancer
14.2.2. Ovarian
Cancer
14.2.3. Colon
cancer
14.2.4. Stomach
Cancer
14.2.5. Head
and Neck Cancer
14.2.6. Prostate
Cancer
14.2.7. Pancreatic
Cancer
14.2.8. Melanoma
14.2.9. Others
14.3. Middle
East and Africa Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
14.3.1. Single
Gene Testing
14.3.2. Multi-Gene
Panel Testing
14.4. Middle
East and Africa Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Diagnostic
Centers
14.4.4. Others
14.5. Middle East
and Africa Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
14.5.1.1.1. Breast Cancer
14.5.1.1.2. Ovarian Cancer
14.5.1.1.3. Colon cancer
14.5.1.1.4. Stomach Cancer
14.5.1.1.5. Head and Neck Cancer
14.5.1.1.6. Prostate Cancer
14.5.1.1.7. Pancreatic Cancer
14.5.1.1.8. Melanoma
14.5.1.1.9. Others
14.5.1.2. Saudi Arabia Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Test Type
14.5.1.2.1. Single Gene Testing
14.5.1.2.2. Multi-Gene Panel Testing
14.5.1.3. Saudi Arabia Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By End Users
14.5.1.3.1. Hospitals
14.5.1.3.2. Clinics
14.5.1.3.3. Diagnostic Centers
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.5.2.1.1. Breast Cancer
14.5.2.1.2. Ovarian Cancer
14.5.2.1.3. Colon cancer
14.5.2.1.4. Stomach Cancer
14.5.2.1.5. Head and Neck Cancer
14.5.2.1.6. Prostate Cancer
14.5.2.1.7. Pancreatic Cancer
14.5.2.1.8. Melanoma
14.5.2.1.9. Others
14.5.2.2. UAE Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
14.5.2.2.1. Single Gene Testing
14.5.2.2.2. Multi-Gene Panel Testing
14.5.2.3. UAE Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts,
By End Users
14.5.2.3.1. Hospitals
14.5.2.3.2. Clinics
14.5.2.3.3. Diagnostic Centers
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.5.3.1.1. Breast Cancer
14.5.3.1.2. Ovarian Cancer
14.5.3.1.3. Colon cancer
14.5.3.1.4. Stomach Cancer
14.5.3.1.5. Head and Neck Cancer
14.5.3.1.6. Prostate Cancer
14.5.3.1.7. Pancreatic Cancer
14.5.3.1.8. Melanoma
14.5.3.1.9. Others
14.5.3.2. Egypt Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
14.5.3.2.1. Single Gene Testing
14.5.3.2.2. Multi-Gene Panel Testing
14.5.3.3. Egypt Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.3.3.1. Hospitals
14.5.3.3.2. Clinics
14.5.3.3.3. Diagnostic Centers
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.5.4.1.1. Breast Cancer
14.5.4.1.2. Ovarian Cancer
14.5.4.1.3. Colon cancer
14.5.4.1.4. Stomach Cancer
14.5.4.1.5. Head and Neck Cancer
14.5.4.1.6. Prostate Cancer
14.5.4.1.7. Pancreatic Cancer
14.5.4.1.8. Melanoma
14.5.4.1.9. Others
14.5.4.2. Kuwait Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
14.5.4.2.1. Single Gene Testing
14.5.4.2.2. Multi-Gene Panel Testing
14.5.4.3. Kuwait Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.4.3.1. Hospitals
14.5.4.3.2. Clinics
14.5.4.3.3. Diagnostic Centers
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South Africa Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
14.5.5.1.1. Breast Cancer
14.5.5.1.2. Ovarian Cancer
14.5.5.1.3. Colon cancer
14.5.5.1.4. Stomach Cancer
14.5.5.1.5. Head and Neck Cancer
14.5.5.1.6. Prostate Cancer
14.5.5.1.7. Pancreatic Cancer
14.5.5.1.8. Melanoma
14.5.5.1.9. Others
14.5.5.2. South Africa Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Test Type
14.5.5.2.1. Single Gene Testing
14.5.5.2.2. Multi-Gene Panel Testing
14.5.5.3. South Africa Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By End Users
14.5.5.3.1. Hospitals
14.5.5.3.2. Clinics
14.5.5.3.3. Diagnostic Centers
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Hereditary Cancer Testing
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.5.6.1.1. Breast Cancer
14.5.6.1.2. Ovarian Cancer
14.5.6.1.3. Colon cancer
14.5.6.1.4. Stomach Cancer
14.5.6.1.5. Head and Neck Cancer
14.5.6.1.6. Prostate Cancer
14.5.6.1.7. Pancreatic Cancer
14.5.6.1.8. Melanoma
14.5.6.1.9. Others
14.5.6.2. Rest of Middle East & Africa Hereditary Cancer Testing
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.5.6.2.1. Single Gene Testing
14.5.6.2.2. Multi-Gene Panel Testing
14.5.6.3. Rest of Middle East & Africa Hereditary Cancer Testing
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.6.3.1. Hospitals
14.5.6.3.2. Clinics
14.5.6.3.3. Diagnostic Centers
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Cancer Type
14.6.3. By Test
Type
14.6.4. By End
Users
15. Latin America Hereditary Cancer Testing Market Analysis and Forecasts,
2021 - 2029
15.1. Overview
15.1.1. Latin
America Hereditary Cancer Testing Market Revenue (US$ Mn)
15.2. Latin
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Cancer Type
15.2.1. Breast
Cancer
15.2.2. Ovarian
Cancer
15.2.3. Colon
cancer
15.2.4. Stomach
Cancer
15.2.5. Head
and Neck Cancer
15.2.6. Prostate
Cancer
15.2.7. Pancreatic
Cancer
15.2.8. Melanoma
15.2.9. Others
15.3. Latin
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Test Type
15.3.1. Single
Gene Testing
15.3.2. Multi-Gene
Panel Testing
15.4. Latin
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By End
Users
15.4.1. Hospitals
15.4.2. Clinics
15.4.3. Diagnostic
Centers
15.4.4. Others
15.5. Latin
America Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts, By
Country
15.5.1. Brazil
15.5.1.1. Brazil Hereditary Cancer Testing Market Revenue (US$ Mn) and Forecasts,
By Cancer Type
15.5.1.1.1. Breast Cancer
15.5.1.1.2. Ovarian Cancer
15.5.1.1.3. Colon cancer
15.5.1.1.4. Stomach Cancer
15.5.1.1.5. Head and Neck Cancer
15.5.1.1.6. Prostate Cancer
15.5.1.1.7. Pancreatic Cancer
15.5.1.1.8. Melanoma
15.5.1.1.9. Others
15.5.1.2. Brazil Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By Test Type
15.5.1.2.1. Single Gene Testing
15.5.1.2.2. Multi-Gene Panel Testing
15.5.1.3. Brazil Hereditary Cancer Testing Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.1.3.1. Hospitals
15.5.1.3.2. Clinics
15.5.1.3.3. Diagnostic Centers
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
15.5.2.1.1. Breast Cancer
15.5.2.1.2. Ovarian Cancer
15.5.2.1.3. Colon cancer
15.5.2.1.4. Stomach Cancer
15.5.2.1.5. Head and Neck Cancer
15.5.2.1.6. Prostate Cancer
15.5.2.1.7. Pancreatic Cancer
15.5.2.1.8. Melanoma
15.5.2.1.9. Others
15.5.2.2. Argentina Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By Test Type
15.5.2.2.1. Single Gene Testing
15.5.2.2.2. Multi-Gene Panel Testing
15.5.2.3. Argentina Hereditary Cancer Testing Market Revenue (US$ Mn)
and Forecasts, By End Users
15.5.2.3.1. Hospitals
15.5.2.3.2. Clinics
15.5.2.3.3. Diagnostic Centers
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
15.5.3.1.1. Breast Cancer
15.5.3.1.2. Ovarian Cancer
15.5.3.1.3. Colon cancer
15.5.3.1.4. Stomach Cancer
15.5.3.1.5. Head and Neck Cancer
15.5.3.1.6. Prostate Cancer
15.5.3.1.7. Pancreatic Cancer
15.5.3.1.8. Melanoma
15.5.3.1.9. Others
15.5.3.2. Rest of Latin America Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By Test Type
15.5.3.2.1. Single Gene Testing
15.5.3.2.2. Multi-Gene Panel Testing
15.5.3.3. Rest of Latin America Hereditary Cancer Testing Market Revenue
(US$ Mn) and Forecasts, By End Users
15.5.3.3.1. Hospitals
15.5.3.3.2. Clinics
15.5.3.3.3. Diagnostic Centers
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Cancer Type
15.6.3. By Test
Type
15.6.4. By End
Users
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2020
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Ambry
Genetics
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. ASPIRA
WOMEN'S HEALTH
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business Strategies
17.3. CENTOGENE N.V.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business Strategies
17.4. Color Health, Inc.
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business Strategies
17.5. Fulgent Genetics
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business Strategies
17.6. Illumina, Inc.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Invitae Corporation
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business Strategies
17.8. LifeLabs Genetics
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business Strategies
17.9. Myogenes Limited
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business Strategies
17.10. Myriad Genetics, Inc.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business Strategies
17.11. NIPD Genetics
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business Strategies
17.12. Otogenetics
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business Strategies
17.13. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.